Positioning strategies in the value-added chain of the biopharmaceutical sector: The case of UK SMEs

Journal of Consumer Marketing

Volumn 21, Issue 7, 2004, Pages 476-485

  Gurǎu, Cǎlin ^a  

^a Prof Mktg Ctr d'Etud Rech S   (France)

Author keywords

Market position; Pharmaceuticals industry; Small to medium sized enterprises; United Kingdom; Value added; Value chain

Indexed keywords

EID: 12144253275     PISSN: 07363761     EISSN: None     Source Type: Journal    
DOI: 10.1108/07363760410568699     Document Type: Article

References (40)

1. Acharya, R. (1999), The Emergence and Growth of Biotechnology, Edward Elgar, Cheltenham.
2. Azzone, G. and Pozza, I.D. (2003), "An integrated strategy for launching a new product in the biotech industry", Management Decision, Vol. 41 No. 9, pp. 832-43.
3. Bank of England (2001), Financing of Technology-Based Small Firms, Domestic Finance Division, Bank of England, London.
4. Bogner, W.C. and Thomas, H. (1996), Drugs to Market: Creating Value and Advantage in the Pharmaceutical Industry, Pergamon Press, Oxford.
5. Boné, E. (1986), "The ethical and social dimensions of biotechnologies", in Davies, D. (Ed.), Industrial Biotechnology in Europe: Issues for Public Policy, Pinter Publishers, London, pp. 99-108.
6. Briggs, P.S. (1994), Biotechnology: A Commercial Evaluation, Script Reports, Richmond, VA.
7. Carson, D., Cromie, S., McGowan, P. and Hill, J. (1995), Marketing and Entrepreneurship in SMEs: An Innovative Approach, Prentice-Hall International, Hemel Hempstead.
8. Chandrasekar, C.R., Helliar, C.V., Lonie, A.A., Nixon, W.A. and Power, D.M. (1999), "Strategic management of innovation risk in the biopharmaceutical industry: a UK perspective", International Journal of Healthcare Technology and Management, Vol. 1 No. 1/2, pp. 62-76.
9. Cockburn, I.M., Henderson, R.M. and Stern, S. (2000), "Untangling the origins of competitive advantage", Strategic Management Journal, Vol. 21, pp. 1123-45.
10. Daly, P. (1985), The Biotechnology Business: A Strategic Analysis, Pinter Publishers, London.
11. Deloitte & Touche (2004), "New growth strategies for biopharmaceutical companies", PRNewswire, 24 February, available at: www.forrelease.com/... 24/nytu129.P1.02242004103547.10378.html (accessed March 2004).
12. Dorabjee, S., Lumley, C.E. and Cartwright, S. (1998), "Culture, innovation and successful development of new medicines - an exploratory study of the pharmaceutical industry", Leadership & Organization Development Journal, Vol. 19 No. 4, pp. 199-210.
13. Euromonitor (1988), The International Biotechnology Handbook, Euromonitor Publications, London.
14. Gattorna, J.L. and Walters, D.W. (1996), Managing the Supply Chain: A Strategic Perspective, Macmillan, London.
15. Grant, R. (1991), "The resource-theory of competitive advantage: implications for strategy formulation", California Management Review, Vol. 33 No. 3, pp. 114-35.
16. Gurǎu, C. (2002), "The Internationalisation Process of UK Biopharmaceutical SMEs", Journal of American Academy of Business, Vol. 2 No. 1, pp. 241-7.
17. Gurǎu, C. and McLaren, Y. (2003), "Corporate reputations in UK biotechnology: an analysis of online 'company profile' texts", Journal of Marketing Communications, Vol. 9 No. 4, pp. 241-56.
18. Hamel, G. and Prahalad, C.K. (1994), Competing for the Future, Harvard Business Press, Boston, MA.
19. Henderson, R. and Cockburn, I. (1994), "Measuring competence? Exploring firm effects in pharmaceutical research", Strategic Management Journal, Vol. 15 No. Winter special issue, pp. 63-84.
20. Jennings, P. and Beaver, G. (1997), "The performance and competitive advantage of small firms: a management perspective", International Small Business Journal, Vol. 15 No. 2, pp. 65-75.
21. Jones, S. (1992), The Biotechnologists, The Macmillan Press, Basingstoke.
22. Keown, B. (1993), "European SMEs gain recognition and research funds", Competitive Edge, Winter, p. 2.
23. Mantegazzini, M.C. (1986), The Environmental Risks from Biotechnology, Pinter Publishers, London.
24. March, I.C. and Gunasekaran, A. (1999), "Business strategy in new high-tech ventures: an empirical analysis", Management Decision, Vol. 37 No. 3, pp. 222-32.
25. McDonald, M.H.B. (1989), Marketing Plans, 2nd ed., Heineman, Oxford.
26. Mintzberg, H. and Waters, J.A. (1985), "Of strategies, deliberate and emergent", Strategic Management Journal, Vol. 6, pp. 257-72.
27. Oakey, R., Faulkner, W., Cooper, S. and Walsh, V. (1990), New Firms in the Biotechnology Industry, Pinter Publishers, London.
28. Persidis, A. (1996), "Building molecular value", Journal of Business Strategy, Vol. 17 No. 2, pp. 18-21.
29. Porter, M.E. (1985), Competitive Advantage: Creating and Sustaining superior Performance, The Free Press, New York, NY.
30. PRTM (2003), "Moving innovation beyond the four walls", Strategic Direction, Vol. 19 No. 7, pp. 36-9.
31. Saviotti, P.P. (1998), "Industrial structure and the dynamics of knowledge generation in biotechnology", in Senker, J. (Ed.), Biotechnology and Competitive Advantage, Edward Elgar, Cheltenham, pp. 19-43.
32. Senker, J. (1998), "Biotechnology: the external environment", in Senker, J. (Ed.), Biotechnology and Competitive Advantage, Edward Elgar, Cheltenham, pp. 6-18.
33. Senker, J., Joly, P.-B. and Reinhard, M. (1998), "Biotechnology and Europe's chemical/pharmaceutical multinationals", in Senker, J. (Ed.), Biotechnology and Competitive Advantage, Edward Elgar, Cheltenham, pp. 110-29.
34. Simkin, L. and Dibb, S. (1998), "Prioritising target markets", Marketing Intelligence & Planning, Vol. 16 No. 7, pp. 407-17.
35. Slatter, S. (1992), Gambling on Growth: How to Manage the Small High-tech Firm, Wiley & Sons, New York, NY.
36. Svensson, G. (2003), "Consumer driven and bi-directional value chain diffusion models", European Business Review, Vol. 15 No. 6, pp. 390-400.
37. Truscheit, E. (1986), "The impact of biotechnology on the pharmaceutical industry", in Davies, D. (Ed.), Industrial Biotechnology in Europe: Issues for Public Policy, Pinter Publishers, London.
38. Walsh, V. (1993), "Demand, public markets and innovation in biotechnology", Science and Public Policy, Vol. 20 No. 3, pp. 138-56.
39. Walsh, V. and Green, K. (1993), "Demand, the public sector and innovation in biotechnology", International Journal of Technology Management, special issue, pp. 28-46.
40. Yonggui, W. and Lo, H.-P. (2002), "Multi-level competition and the integrated hierarchical model of competitive advantages in turbulent environments: a resource-based view", foresight, Vol. 4 No. 3, pp. 38-50.